News
CDTX
23.43
+0.13%
0.03
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders
Seeking Alpha · 2d ago
Cidara Therapeutics files to sell 7.04M shares of common stock for holders
TipRanks · 2d ago
Twelve option delistings on December 23rd
TipRanks · 2d ago
Weekly Report: what happened at CDTX last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at CDTX last week (1209-1213)?
Weekly Report · 12/16 10:28
Cidara Therapeutics Price Target Announced at $34.00/Share by RBC Capital
Dow Jones · 12/13 14:36
RBC Capital Initiates Coverage On Cidara Therapeutics with Outperform Rating, Announces Price Target of $34
Benzinga · 12/13 14:26
Cidara Therapeutics initiated with an Outperform at RBC Capital
TipRanks · 12/13 11:15
Weekly Report: what happened at CDTX last week (1202-1206)?
Weekly Report · 12/09 10:26
Innovative Influenza Prevention and Strategic Moves Elevate Cidara Therapeutics’ Stock Potential
TipRanks · 12/05 17:48
Cidara Therapeutics Is Maintained at Strong Buy by WBB Securities
Dow Jones · 12/05 15:12
Cidara Therapeutics Price Target Raised to $45.00/Share From $40.00 by WBB Securities
Dow Jones · 12/05 15:12
WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $45
Benzinga · 12/05 15:02
VENROCK HEALTHCARE CAPITAL PARTNERS III LP REPORTS 9.99% PASSIVE STAKE IN CIDARA THERAPEUTICS INC AS OF NOVEMBER 26 - SEC FILING
Reuters · 12/04 21:20
Cidara's Phase II Trial Testing CD388 For Flu Prevention Fully Enrolled With 5,000 Subjects
NASDAQ · 12/04 16:34
Cidara Therapeutics completes enrollment of Phase 2b NAVIGATE trial
TipRanks · 12/04 13:10
CIDARA THERAPEUTICS COMPLETES ENROLLMENT OF PHASE 2B NAVIGATE TRIAL EVALUATING CD388 FOR PREVENTION OF SEASONAL INFLUENZA
Reuters · 12/04 13:00
TCG CROSSOVER GP II, LLC REPORTS 9.2% PASSIVE STAKE IN CIDARA THERAPEUTICS INC AS OF NOV 26 - SEC FILING
Reuters · 12/03 21:37
Weekly Report: what happened at CDTX last week (1125-1129)?
Weekly Report · 12/02 10:27
Weekly Report: what happened at CDTX last week (1118-1122)?
Weekly Report · 11/25 10:22
More
Webull provides a variety of real-time CDTX stock news. You can receive the latest news about Cidara Theraptcs through multiple platforms. This information may help you make smarter investment decisions.
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.